SCWorx Resumes Nasdaq Trading as Gross Profit Jumps 122%

SCWorx Corp. (Nasdaq: WORX) resumed trading on The Nasdaq Capital Market on 7 October 2026, after the Nasdaq Hearings Panel granted its request for reconsideration and determined the company had regained compliance with continued listing requirements. The Middleton, Massachusetts-based healthcare data company reported first-half 2026 gross profit of approximately $705,000, up 122% from approximately $317,000 a year earlier, while its net loss narrowed to approximately $295,000 from approximately $2.4 million.

Context — Why the Nasdaq Relisting Matters Now

The relisting follows a September 17, 2026 delisting decision that the panel reversed on October 2. The reversal carries conditions, including a one-year Panel Monitor, which the company disclosed in a Form 8-K filed with the Securities and Exchange Commission on October 5, 2026. Under that monitor, any future deficiency would trigger a Staff Delisting Determination without a compliance plan or cure period.

That condition is the central risk attached to the relisting. A normal Nasdaq deficiency gives a company a defined cure window; SCWorx has effectively traded that window for immediate reinstatement, meaning the next listing miss would be terminal rather than negotiable.

The company also flagged that the Nasdaq Listing and Hearing Review Council could still call the October 2 decision for review, and that investors in its September 2026 private placement hold contractual termination rights. Neither event has occurred; both are disclosed possibilities.

The timing matters because SCWorx is trying to convert an improved cost structure into commercial momentum. The company said it has spent more than a decade building healthcare-specific product data, classification methodologies and attribute structures, and during 2026 it began layering commercially available large language models on top of those assets through what it calls an AI-enabled Data Management Model.

CEO Tim Hannibal framed the listing as a platform rather than an endpoint, saying the company's focus "remains firmly on the underlying business." The company's own outlook language is explicit that long-term success depends on operating performance and execution, not on the listing itself.

Data — What the Numbers Show

The second quarter of 2026 produced revenue of approximately $706,000, against approximately $683,000 in the second quarter of 2025. Gross profit for that quarter rose roughly 83% to approximately $330,000 from approximately $180,000. The first half tells the sharper story: revenue of approximately $1.45 million versus approximately $1.40 million, but gross profit of approximately $705,000 versus approximately $317,000.

Metric	H1 2025	H1 2026	Change
Revenue	~$1.40M	~$1.45M	+3.6%
Gross profit	~$317K	~$705K	+122%
Net loss	~$2.4M	~$295K	-88%
Operating cash used	~$1.1M	~$258K	-77%

Revenue grew roughly 3.6% while gross profit more than doubled, which is the operating-use claim in numerical form. The company attributed the narrower net loss to higher gross profit and to the absence in 2026 of approximately $1.7 million of interest expense and amortization of debt discount tied to convertible notes that are no longer outstanding. Operating expenses were essentially unchanged.

Cash used in operating activities fell to approximately $258,000 in the first half from approximately $1.1 million a year earlier. SCWorx held approximately $1.3 million of cash at June 30, 2026, and in September 2026 raised gross proceeds of $938,000 through a private placement of common stock and warrants.

Analysis — What It Means for Healthcare Tech and Small Caps

The gross-margin shift is the part of this release that carries weight beyond the listing headline. A company growing revenue 3.6% while lifting gross profit 122% is reporting a mix change, not a demand change. For a data-management vendor, that usually means lower delivery cost per unit of work — here attributed to AI-enabled automation combined with existing curated data assets.

If that margin profile holds, the operating use is real for a business whose main input is human data-cleansing labor. The counter-argument is that a single half-year is a thin sample, operating expenses were flat rather than falling, and the company remains unprofitable at approximately $295,000 of net loss. The improvement is directional, not yet a proven run rate.

Exposure sits with small-cap healthcare IT and supply chain data vendors competing for the same hospital IT budgets, and with the ERP channel — the company cited a not-for-profit teaching hospital using its data-management capabilities to support a Workday implementation, and a two-year agreement with one of Massachusetts' largest integrated delivery networks. Workday is the named platform in that first relationship; SCWorx is the data layer beneath it.

The capital structure is the constraint. With approximately $1.3 million of cash at June 30 and $938,000 raised in September, the runway is short relative to the stated growth ambitions, and the private placement introduced dilution plus the termination rights the company disclosed. Positioning reflects that tension: the relisting removes a forced-seller overhang, but the one-year Panel Monitor keeps institutional buyers cautious until revenue growth, not just margin, shows up in the filings.

Outlook — What to Watch Next

The next hard datapoint is the third-quarter Form 10-Q, which will show whether the 122% gross-profit gain persisted past June 30 and whether operating cash use stayed near the $258,000 half-year level. The company gave no date for that filing in this release.

Investors should also track whether the Nasdaq Listing and Hearing Review Council calls the October 2 decision for review, and whether the September 2026 private-placement investors act on their contractual termination rights. Both are binary events disclosed by the company with no resolution timeline attached.

On the commercial side, the metrics that matter are recurring and multi-year revenue as a share of total revenue — a stated priority the company did not quantify — and any new hospital or channel agreements announced during the Panel Monitor period. Revenue growth remains the missing piece: a 3.6% half-year increase is well below what the improved cost base needs to convert into positive cash flow.

Frequently Asked Questions

What does the SCWorx Nasdaq relisting mean for existing shareholders?

The October 2 panel decision restored trading and removed the immediate delisting risk, but it attached a one-year Panel Monitor. During that period, any listing deficiency would produce a Staff Delisting Determination without a compliance plan or cure period. Shareholders therefore hold a stock with restored liquidity but a narrower margin for error on compliance than a standard Nasdaq listing.

Why did SCWorx's net loss fall 88% in the first half of 2026?

Two factors drove it. Gross profit rose to approximately $705,000 from approximately $317,000, and the company recorded no interest expense or amortization of debt discount in 2026, versus approximately $1.7 million in the first half of 2025 tied to convertible notes that are no longer outstanding. Operating expenses were essentially unchanged between the two periods.

How does SCWorx's AI-enabled Data Management Model actually work?

It combines commercially available large language models with SCWorx's own healthcare data assets, attribute catalog, classification methodologies and human quality-assurance processes. The company says the goal is faster cleansing, normalization, classification and enrichment of supply chain data at lower resource cost. SCWorx has not disclosed pricing, customer count or revenue attributable to the model.

Bottom Line

SCWorx restored its Nasdaq listing and doubled first-half gross profit, but 3.6% revenue growth and a one-year Panel Monitor leave execution unproven.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.